Cargando…

Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries

The aim of this paper is to identify the barriers that are specifically relevant to the use of Artificial Intelligence (AI)-based evidence in Central and Eastern European (CEE) Health Technology Assessment (HTA) systems. The study relied on two main parallel sources to identify barriers to use AI me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tachkov, Konstantin, Zemplenyi, Antal, Kamusheva, Maria, Dimitrova, Maria, Siirtola, Pekka, Pontén, Johan, Nemeth, Bertalan, Kalo, Zoltan, Petrova, Guenka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330148/ https://www.ncbi.nlm.nih.gov/pubmed/35910914 http://dx.doi.org/10.3389/fpubh.2022.921226

Ejemplares similares

Potential Barriers of Patient Involvement in Health Technology Assessment in Central and Eastern European Countries
por: Dimitrova, Maria, et al.
Publicado: (2022)

Can cost–effectiveness principles be ignored in urgent times?
por: Kaló, Zoltán, et al.
Publicado: (2021)

Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making
por: Németh, Bertalan, et al.
Publicado: (2023)

Pharmacotherapeutic Patterns and Patients’ Access to Pharmacotherapy for Some Rare Diseases in Bulgaria – A Pilot Comparative Study
por: Kamusheva, Maria, et al.
Publicado: (2021)

Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment
por: Zemplényi, Antal, et al.
Publicado: (2023)

Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting
por: Dimitrova, Maria, et al.
Publicado: (2014)

Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries?
por: Kovács, Sándor, et al.
Publicado: (2022)

Analysis of Healthcare Expenditures in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2022)

Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2019)

A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care
por: Kamusheva, Maria, et al.
Publicado: (2021)

Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2022)

Review of medicine utilization for Parkinson’s disease management: The Bulgarian perspective
por: Mitkova, Zornitsa, et al.
Publicado: (2021)

Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: prophylactic vs. on-demand treatment
por: Petrova, Guenka, et al.
Publicado: (2014)

New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria
por: Kamusheva, Maria, et al.
Publicado: (2020)

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
por: Boyadzieva, Vladimira V., et al.
Publicado: (2018)

Development of transferability guidance for integrated care models with special focus on Central and Eastern European countries
por: Kaló, Zoltán, et al.
Publicado: (2020)

Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy
por: Petrova, Guenka, et al.
Publicado: (2017)

Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2020)

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Recommendations for patient involvement in health technology assessment in Central and Eastern European countries
por: Jakab, Ivett, et al.
Publicado: (2023)

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
por: Stoeva, Vera, et al.
Publicado: (2023)

The European challenges of funding orphan medicinal products
por: Szegedi, Márta, et al.
Publicado: (2018)

Delayed payment schemes in Central-Eastern Europe and Middle-East
por: Ádám, Ildikó, et al.
Publicado: (2022)

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges
por: Daubner-Bendes, Rita, et al.
Publicado: (2021)

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Evaluation of potentially inappropriate medication in older patients with cardiovascular diseases—STOPP/START-based study
por: Krustev, Tzvetan, et al.
Publicado: (2022)

Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib—A Real-Life Longitudinal Study
por: Stoeva, Vera, et al.
Publicado: (2023)

Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts
por: Inotai, Andras, et al.
Publicado: (2018)

Comparative analysis of the access to health-care services and breast cancer therapy in 10 Eastern European countries
por: Dimitrova, Maria, et al.
Publicado: (2020)

How Managed Entry Agreements Influence the Patients’ Affordability to Biological Medicines—Bulgarian Example
por: Mitkova, Zornitsa, et al.
Publicado: (2023)

Chronic Hepatitis C-Related Cirrhosis Hospitalization Cost Analysis in Bulgaria
por: Dimitrova, Maria, et al.
Publicado: (2017)

Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for Patients in Slovakia with Advanced Diabetic Foot Ulcer
por: Tesar, Tomas, et al.
Publicado: (2017)

Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries - The Case of Bulgaria, Romania, and Poland
por: Kamusheva, Maria, et al.
Publicado: (2021)

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
por: Manova, Manoela, et al.
Publicado: (2018)

Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects
por: Mitkova, Zornitsa, et al.
Publicado: (2019)

Outcome-based reimbursement in Central-Eastern Europe and Middle-East
por: Ádám, Ildikó, et al.
Publicado: (2022)

Adherence to Acromegaly Treatment and Analysis of the Related Factors—A Real-World Study in Bulgaria
por: Kamusheva, Maria, et al.
Publicado: (2023)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4dc6fq0dootvdd2p0v7u8n7bab